Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.41 USD | +0.71% | +6.02% | +5.22% |
04-24 | Precigen, Inc. to Present Late-Breaking Abstract for Pivotal Phase 2 Study Data for PRGN- 2012 AdenoVerse Immunotherapy | CI |
03-25 | North American Morning Briefing : Tech in Focus on -2- | DJ |
Evolution of the average Target Price on Precigen, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Precigen, Inc.
JPMorgan Chase | |
Cantor Fitzgerald | |
HC Wainwright | |
Stifel Nicolaus | |
B. Riley |
EPS Revisions
- Stock Market
- Equities
- PGEN Stock
- Consensus Precigen, Inc.